We hypothesize that IL-13 is synergistic with IL-4 in inducing immunotherapy resistance on the one hand, and that it is the result of cytokine storms induced by tumor progression of resistance on the other (Fig. 1E). The gene discussed is IL13; the disease is neoplasm.